Experimental drug improves muscle strength among male cancer patients
An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented at The Endocrine Society's 94th ...
Medical research
Jun 25, 2012 |
not rated yet |
0
Testosterone therapy does not up prostate cancer incidence
(HealthDay) -- Testosterone replacement therapy (TRT) appears to be safe and does not increase the incidence of prostate cancer, according to a study published online June 6 in The Journal of Sexual Medicine.
Cancer
Jun 15, 2012 |
5 / 5 (1) |
0
|
Capability of curry component to treat disease merits US patent
A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.
Medical research
Jun 12, 2012 |
3.7 / 5 (3) |
2
New target, new drug in breast cancer
Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...
Cancer
Jun 04, 2012 |
5 / 5 (1) |
0
Do bald men face higher risk of prostate cancer?
(HealthDay) -- Got hair? If you don't, you might have a higher risk of prostate cancer, a preliminary study suggests.
Cancer
May 22, 2012 |
5 / 5 (1) |
0
|
Hormone-depleting drug shows promise against localized high-risk prostate tumors
A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, ...
Cancer
May 16, 2012 |
5 / 5 (1) |
0
Low testosterone levels could raise diabetes risk for men
Low levels of testosterone in men could increase their risk of developing diabetes, a study suggests.
Medical research
May 04, 2012 |
5 / 5 (1) |
0
|
BMD loss occurs early in androgen deprivation therapy
(HealthDay) -- The highest average change in bone mineral density (BMD) occurs during early treatment of nonmetastatic, hormone-sensitive prostate cancer in men receiving intermittent androgen deprivation ...
Cancer
Apr 11, 2012 |
not rated yet |
0
Early clinical data show galeterone safe, effective against prostate cancer
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data ...
Cancer
Apr 01, 2012 |
5 / 5 (1) |
0
Androgen suppression
Androgen suppression – the inhibition of testosterone and other male hormones – is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, ...
Cancer
Mar 27, 2012 |
4 / 5 (1) |
0
Study role testosterone may play in triple negative breast cancer
Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. ...
Cancer
Mar 23, 2012 |
5 / 5 (1) |
0
|
Androgen boosts hepatitis B virus replication
Androgen enhances replication of hepatitis B virus (HBV), rendering males more vulnerable than females to this virus, according to research published in the February Journal of Virology.
Diseases, Conditions, Syndromes
Feb 16, 2012 |
not rated yet |
0
Curry spice component may help slow prostate tumor growth
Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers ...
Cancer
Feb 10, 2012 |
4.5 / 5 (10) |
0
|
Study identifies new prostate cancer drug target
Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...
Cancer
Feb 06, 2012 |
5 / 5 (2) |
0
|
New drug extends survival in patients with drug-resistant prostate cancer
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression ...
Cancer
Feb 01, 2012 |
5 / 5 (1) |
0
|
